What you carry at this position in your DNA and what research says about it.
Viral Defense and Sleep: 6/10 evidence, 37 publications.
You're viewing every possible genotype for this variant.
None of these is your result. Use the genotype toggle to compare them, then sign up and upload your DNA to see which one is yours.
Sample genotype (not yours): A/A
Optimal Viral Clearance and Lower Insomnia Risk
Excellent natural defenses help clear viral infections and respond highly to traditional hepatitis treatments. Sleep patterns tend to be more stable with a lower baseline risk of insomnia.
What this genotype means: Highly effective natural clearance of hepatitis C; Excellent response to interferon-based therapies; Lower risk of chronic insomnia.
Sample genotype (not yours): A/G
Intermediate Viral Defense and Typical Insomnia Risk
A single copy of the protective allele provides moderate viral clearance capabilities and typical treatment response rates. Sleep patterns and inflammatory risks generally fall within the average range.
What this genotype means: Moderate natural clearance rate for hepatitis C; Average response to interferon-based therapies; Typical baseline risk of insomnia.
Sample genotype (not yours): G/G
Reduced Viral Clearance and Higher Insomnia Risk
Lower natural viral clearance rates make responding to traditional hepatitis therapies more challenging. There is also an elevated risk of insomnia and certain inflammatory complications.
What this genotype means: Lower likelihood of spontaneous hepatitis C clearance; Poorer response to interferon-based therapies; Increased risk of chronic insomnia.
Gene function and biological role
Gene Function: IFNL3 encodes interferon lambda 3, a cytokine that plays a critical role in the innate immune response against viral infections [1]. This protein is particularly vital in the liver, where it helps orchestrate the defense against hepatotropic viruses like hepatitis C [2]. Genetic variations near this gene are among the strongest known predictors of whether a person can naturally clear the hepatitis C virus or respond to interferon-based therapies [3]. Additionally, these variations influence broader immune responses, affecting susceptibility to inflammatory complications during other medical treatments [4].
Variant Impact: This intergenic variant is located near the IFNL3 gene on chromosome 19 and serves as a powerful marker for immune system activity. The genetic change alters how efficiently the body responds to viral threats and certain immunotherapies [4]. It is strongly linked to the likelihood of achieving a sustained virologic response during hepatitis C treatment [2]. Beyond viral infections, the variant is associated with differences in baseline lipid levels, specifically low-density lipoprotein cholesterol [5]. It also correlates with the risk of developing sleep disturbances like insomnia [6].
Key Insight: This genetic marker is one of the strongest predictors of whether the body can naturally clear the hepatitis C virus without medication.
Location: IFNL3. Chromosome 19 · 19q13.2 · 39.2 Mb
Estimated prevalence by population
Global 42.8%; European 48.7%; African 23.2%; East Asian 84.7%; South Asian 61.5%; Americas 39.8%; Ashkenazi 35.6%; Finnish 60.4%; Middle Eastern 39.6%; Amish 44.9%.
Estimated AA genotype frequency.
Global 43.2%; European 42.2%; African 49.9%; East Asian 14.6%; South Asian 33.9%; Americas 46.6%; Ashkenazi 48.1%; Finnish 34.6%; Middle Eastern 46.7%; Amish 44.2%.
Estimated AG genotype frequency.
Global 14.0%; European 9.1%; African 26.9%; East Asian 0.6%; South Asian 4.7%; Americas 13.7%; Ashkenazi 16.3%; Finnish 5.0%; Middle Eastern 13.7%; Amish 10.9%.
Estimated GG genotype frequency.
Showing effects for A/A genotype
Immunity & Inflammation
Infection Susceptibility & Resistance
Hepatitis C Clearance. Evidence: 6/10. Source: PMID 25769643. Enhanced Clearance.
Neurology & Mental Health
Sleep & Circadian Rhythm
Insomnia. Evidence: 6/10. Source: PMID 35835914. Typical Risk.
Cardiovascular & Metabolic
Lipids & Cholesterol
LDL Cholesterol. Evidence: 4/10. Source: PMID 22497812. Slightly Higher.
Pharmacogenomics
Chemotherapy Response
Immunotherapy Safety. Evidence: 5/10. Source: PMID 40743639. Typical Risk.
Lifestyle, Fitness & Aging
Injury Risk & Recovery
Surgical Recovery. Evidence: 3/10. Source: PMID 32478085. Typical Risk.
Showing effects for A/G genotype
Hepatitis C Clearance. Evidence: 6/10. Source: PMID 25769643. Typical Clearance.
Insomnia. Evidence: 6/10. Source: PMID 35835914. Slightly Increased.
LDL Cholesterol. Evidence: 4/10. Source: PMID 22497812. Typical.
Showing effects for G/G genotype
Hepatitis C Clearance. Evidence: 6/10. Source: PMID 25769643. Reduced Clearance.
Insomnia. Evidence: 6/10. Source: PMID 35835914. Increased Risk.
LDL Cholesterol. Evidence: 4/10. Source: PMID 22497812. Slightly Lower.
Immunotherapy Safety. Evidence: 5/10. Source: PMID 40743639. Higher Lung Risk.
Surgical Recovery. Evidence: 3/10. Source: PMID 32478085. Higher Shock Risk.
What this genotype means for the people who carry it
Sample genotype: AA (Homozygous)
Two copies of the A allele provide highly favorable immune system performance and viral defense. Clinical studies show that this genotype is associated with a significantly higher rate of spontaneous clearance of the hepatitis C virus [1]. If treatment is required, it predicts an excellent response to peginterferon and ribavirin therapies [2]. Beyond viral defense, this genetic profile is linked to a lower risk of developing insomnia compared to carriers of the G allele [3]. It also provides a protective effect against severe inflammatory complications, such as lung inflammation during cancer immunotherapy [4]. Furthermore, patients undergoing major surgeries have a lower risk of septic shock-related mortality with this genotype [5]. Although baseline LDL cholesterol levels may be slightly higher, the overall health profile remains highly favorable [6].
Highly effective natural clearance of hepatitis C; Excellent response to interferon-based therapies; Lower risk of chronic insomnia.
Sample genotype: AG (Heterozygous)
An intermediate clinical profile for viral clearance and immune response is typical for this genetic makeup. Response rates to traditional hepatitis C therapies are variable and generally lower than those with the A/A genotype, but still better than G/G carriers [1]. Natural clearance of the virus is also moderately successful but not guaranteed [2]. Sleep patterns are typical, with only a very slight increase in insomnia risk compared to the protective genotype [3]. Risks for severe surgical complications or immunotherapy-induced lung inflammation remain close to the population average [4] [5]. Baseline LDL cholesterol levels are typically average, reflecting a balanced genetic influence [6].
Moderate natural clearance rate for hepatitis C; Average response to interferon-based therapies; Typical baseline risk of insomnia.
Sample genotype: GG (Homozygous)
Two copies of the G allele are associated with a less active interferon-driven immune response. This genotype is linked to a significantly lower rate of spontaneous hepatitis C clearance and a poorer response to interferon-based treatments [1]. Sleep quality may be affected, as this profile is associated with an increased risk of chronic insomnia [2]. During cancer treatments using immune checkpoint inhibitors, there is an elevated risk of developing severe lung inflammation [3]. Major surgeries also carry a higher risk of septic shock-related mortality for individuals with this genetic makeup [4]. On a positive note, this genotype is associated with lower baseline levels of low-density lipoprotein cholesterol [5]. However, the overall clinical picture points to a higher susceptibility to inflammatory and infectious challenges.
Lower likelihood of spontaneous hepatitis C clearance; Poorer response to interferon-based therapies; Increased risk of chronic insomnia.
Variants with shared genetic architecture
rs8099917 · IFNL3 Gene · Chr 19 · Hepatitis C Treatment Response
rs11881222 · IFNL3 Gene · Chr 19 · Hepatitis C Clearance
rs8105790 · IFNL3 Gene · Chr 19 · Hepatitis Viral Clearance
IL28B polymorphisms associated with therapy response in Chilean chronic hepatitis C patients.
Content updated August 2026.
ReadYourDNA provides educational interpretation of DNA data you already have. It is not diagnostic, not a substitute for professional medical advice, diagnosis, or treatment, and is not intended to diagnose, treat, cure, or prevent any disease. Talk to a clinician before acting on any result.
Raw DNA Data Reports for 23andMe & AncestryDNA · About ReadYourDNA · FAQ · Methodology & Science · Pricing · Support and complaints · Legal & Contact · Health Traits · Pharmacogenomics · Carrier Status · Variant Explorer · The Human Karyotype · Privacy Policy · Terms of Service · Accessibility · Consumer Health Data Privacy · Your Privacy Choices · Editorial Standards · Your Data, Checkable · Sample Report · ReadYourDNA and Promethease compared · What is inside a 23andMe raw data file · What is inside an AncestryDNA raw data file · What a chatbot can and cannot do with your raw DNA file · Where a raw DNA file can still be uploaded in 2026
Written, maintained and operated by Martin Pechhacker, sole proprietor, Vienna, Austria. Trade register GISA 40064420. support@readyourdna.com